BARD1 anticorps (AA 1-80)
Aperçu rapide pour BARD1 anticorps (AA 1-80) (ABIN7213766)
Antigène
Voir toutes BARD1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 1-80
-
Fonction
- Rabbit Anti-BARD1 Polyclonal Antibody
-
Specificité
- BARD1 Polyclonal Antibody detects endogenous levels of BARD1 protein.
-
Purification
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-
Immunogène
- Synthesized peptide derived from the N-terminal region of human BARD1 at AA range: 1-80
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,IHC 1:100-1:300,ELISA 1:5000,IF 1:50-200
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
-
Date de péremption
- 12 months
-
-
- BARD1 (BRCA1 Associated RING Domain 1 (BARD1))
-
Autre désignation
- BARD1
-
Sujet
- BARD1, BRCA1-associated RING domain protein 1, BARD-1BARD1 encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for BARD1.
-
Poids moléculaire
- 79kD
-
ID gène
- 580
-
UniProt
- Q99728
-
Pathways
- Réparation de l'ADN
Antigène
-